Abstract
median 470.5 mcg/g 3 months after starting anti-TNF (n = 22). 39 infusion reactions were observed in IFX-treated patients; 6 followed a treatment break of 147 1568 days. 10 serum sickness-like reactions were observed (8 with IFX, 2 with ADA). Conclusions: Outcome of changes in treatment patterns will inform unanswered questions regarding patient selection and length of therapy. Drug holiday from IFX remains an indication for ADA. Innovations in monitoring response to anti-TNF, notably recording of Harvey Bradshaw Index and FC before every treatment (initiated in our centre during 2011) will further aid decision-making.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
